C520 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginSustained revenue expansion combined with a ~60% gross margin provides durable operating leverage potential. As procedure volumes and product mix continue improving, the high gross margin gives room to absorb SG&A and R&D while converting top-line gains into lasting margin recovery.
Improving Cash Generation And FCF TargetImproving operating cash flow and a management target to convert >25% of revenue into free cash flow are durable positives. Stronger FCF reduces reliance on external financing, funds ongoing R&D/CapEx, supports integration of acquisitions, and enhances balance sheet optionality over months to years.
Innovation Pipeline & ASC PenetrationNew systems (Arvis, Nebula) and rising ASC adoption create structural commercial tailwinds. Flexible commercial models and instrumentation rollouts help win conversions and capture procedure share, supporting sustainable revenue mix improvement and recurring instrument/service demand.
Bears Say
Sharp Profitability DeteriorationVery large operating losses and roughly -50% net margins are a durable structural concern. Until fixed-cost absorption and operating discipline materially improve, earnings recovery depends on sustained top-line growth and margin expansion, making cash profits uncertain.
Tariff Cost HeadwindRecurring tariff costs represent a persistent margin headwind, particularly in the lower-growth P&R segment. Management assumes no refunds; sustained tariffs can erode gross and adjusted margins, force price actions, or necessitate ongoing productivity gains to protect profitability.
Capital Structure VolatilityHistoric swings in leverage and deeply negative returns on equity indicate capital structure instability. If cash generation weakens or acquisitions continue, refinancing or dilution risk rises. Persistent negative ROE limits shareholder returns until profits normalize.
Enovis News
C520 FAQ
What was Enovis’s price range in the past 12 months?
Currently, no data Available
What is Enovis’s market cap?
Enovis’s market cap is CHF1.36B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Aug 06, 2026 which is tomorrow.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on May 07, 2026. The company reported CHF0.72 earnings per share for the quarter, beating the consensus estimate of CHF0.657 by CHF0.063.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.68.
How many shares outstanding does Enovis have?
Enovis has 57,562,603 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of CHF0.72 in its last earnings report, beating expectations of CHF0.657. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in CH:C520
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF33.25 (― Upside)
CHF33.25 (― Upside)
Blogger Sentiment
Bullish
CH:C520 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth CHF74.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
C520 Company Deck
C520 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all CH:C520 earnings summaries